Actively Recruiting
Phase 2 Study of Co-Administered Novel Oral Poliovirus Vaccines nOPV1 and nOPV2 Compared to Each Vaccine Alone in Healthy Infants in Panama
Led by PATH · Updated on 2026-01-09
675
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and immune response of co-administering two novel oral poliomyelitis vaccines, nOPV1 and nOPV2, in healthy infants. The study compares infants receiving both vaccines together to those given each vaccine alone, assessing whether two or three doses of the combined vaccines are as effective as the individual vaccines. This is a Phase 2, randomized, double-dummy, observer-blind study involving infants around 16 weeks old. Participants are randomly assigned to one of three groups nOPV1 with a placebo, nOPV2 with a placebo, or both nOPV1 and nOPV2 together. Vaccinations are given at 16, 20, and 24 weeks of age. Blood samples for immune testing are collected at these ages and again at 28 weeks to measure antibody responses. Stool samples are also gathered to check for virus shedding after vaccination. During the study, infants are observed for immediate reactions for at least 30 minutes after vaccination. Parents record any local or systemic reactions for 7 days following each dose, while unsolicited side effects are tracked for 28 days after each vaccination. Serious adverse events are monitored throughout the study. The study measures include rates of adverse events and the percentage of infants developing protective antibodies against poliovirus types 1 and 2, with participation lasting until about 28 weeks of age.
CONDITIONS
Brief Title
Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation
Research Team
X
Xavier Saez-Llorens
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here